Can a vitamin pill reverse hair loss from Weight-Loss drugs?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 20 to 60 years. * Dry, normal, combination, or oily scalp type. * Clinical diagnosis of telogen effluvium associated with the use of GLP-1 receptor agonists (semaglutide or tirzepatide), diagnosed by a dermatologist and confirmed by trichogram analysis. * Hair length of at least 3 cm. * Use of GLP-1 receptor agonists (semaglutide or tirzepatide) for at least 3 months prior to enrollment. * Intact skin in the study area (scalp). * Use of GLP-1 receptor agonists approved by ANVISA and commercially available in Brazil. * Under regular medical supervision during the study period. * Loss of at least 5% of initial body weight prior to enrollment. * Willingness to maintain the same hairstyle, haircut, and hair care habits throughout the study. * Willingness to comply with all study procedures and requirements. * Ability to provide written informed consent. Exclusion Criteria: * Pregnancy, breastfeeding, postpartum period up to 6 months, or intention to become pregnant during the study. * Scalp conditions or skin marks that may interfere with study assessments. * Known allergy or hypersensitivity to any component of the investigational product or similar products. * Active scalp disorders that could interfere with study evaluations, including scarring alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate-to-severe seborrheic dermatitis, or eczema. * Use of nonsteroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizing agents, or immunosuppressants within 2 weeks before enrollment. * Ongoing radiotherapy or chemotherapy treatment. * Hair chemical procedures within 30 days prior to enrollment. * Recent use or dose adjustment of medications known to induce telogen effluvium. * Use of dietary supplements for hair loss within the previous 3 months. * Use of hair loss treatments or hair cycle modulators (e.g., minoxidil, finasteride, dutasteride, spironolactone) within the previous 3 months. * Hair transplantation within the previous 18 months. * Use of topical dermatological products for therapeutic or specific cosmetic purposes on the study area (scalp), such as hair tonics, topical minoxidil, medicated lotions, or acid-based treatments, within 48 hours prior to study initiation. * Initiation, discontinuation, or modification of hormone therapy within the previous 3 months. * Uncontrolled systemic diseases, including diabetes, lupus, thyroid disorders, anemia, or documented iron deficiency. * Bariatric surgery within the previous 12 months. * Hair loss associated with COVID-19 infection within the previous 6 months. * Hospitalization within the previous 6 months. * Major physical or psychological stressors within the previous 3 months. * Uncontrolled endocrine disorders. * History or evidence of alcohol or substance abuse. * Immunosuppression caused by medications or active diseases. * Excessive sun exposure or artificial tanning within 15 days before the baseline visit. * Participation in another clinical study. * Investigator site staff or family members directly involved in the study. * Any condition that, in the investigator's opinion, may compromise participant safety or study integrity.